The chemokine receptor
CXCR7, also known as ACKR3, is a seven-transmembrane
G-protein-coupled receptor (GPCR) involved in various pathologies
such as neurological diseases, autoimmune diseases, and cancers. By
binding and scavenging the chemokines CXCL11 and CXCL12, CXCR7 regulates
their extracellular levels. From an original high-throughput screening
campaign emerged hit 3 among others. The hit-to-lead
optimization led to the discovery of a novel chemotype series exemplified
by the trans racemic compound 11i. This series provided
CXCR7 antagonists that block CXCL11- and CXCL12-induced ß-arrestin
recruitment. Further structural modifications on the trisubstituted
piperidine scaffold of 11i yielded compounds with high
CXCR7 antagonistic activities and balanced ADMET properties. The effort
described herein culminated in the discovery of ACT-1004-1239 (28f). Biological characterization of ACT-1004-1239 demonstrated
that it is a potent, insurmountable antagonist. Oral administration
of ACT-1004-1239 in mice up to 100 mg/kg led to a dose-dependent increase
of plasma CXCL12 concentration.
Recently, a number of novel quinolones with potent activity against topoisomerase H and eukaryotic cells have been described. Many of these compounds contain aromatic substituents in their C-7 ring positions. To determine whether pyrimido[1,6-albenzimidazoles, a class of drugs modeled on quinolones, also display activity toward eukaryotic systems, the effects of Ro 46-7864 and Ro 47-3359 on Drosophila melanogaster topoisomerase II and Kc cells were characterized. While the former drug contains an aliphatic group (4-N-methylpiperazine) at the ring position equivalent to C-7 in quinolones, the latter compound contains an aromatic substituent (2,6-dimethylpyridine). Both pyrimido [1,6-
The synthesis and structure-activity relationships of a new class of vinylcephalosporins substituted with a lactamyl residue are described. These compounds show excellent activity against enterococci and retain the broad spectrum activity of third-generation cephalosporins such as ceftriaxone.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.